Results about: mitochondria
Age-related metabolic diseases have increased to epidemic proportions in all industrialized countries.
Our research addresses the evolution of the protein synthesis machinery, the molecular interactions that regulate it, and the biomedical applications that can be derived from its study. Our research projects are focused around the biology of transfer RNA (tRNA).
Researchers discover activators of a potential therapeutic target for the treatment of patients with diabetes and insulin resistance
A team headed by Antonio Zorzano at IRB Barcelona has identified activators of the mitochondrial protein Mitofusin 2 for the treatment of type 2 diabetes.
The protein is a key regulator of many mitochondrial functions, as well as of the cell as a whole.
The 2017 IRB Barcelona Alumni of Excellence Award has gone to Marc Liesa, who obtained his PhD in 2008 in Antonio Zorzano’s Complex Metabolic Diseases and Mitochondria Laboratory. The award, established in 2016, acknowledges the excellence of former IRB Barcelona scientists and is given with the support of Eppendorf. Liesa visited the Institute on 5 May to receive the distinction. He talks about his science and shares some secrets of his success.
IRB Barcelona researchers discover that the loss of the protein Mitofusin 2 in the muscles of young mice speeds up aging and causes early sarcopenia, thus leading to the muscle quality of aged mice.
Sarcopenia, which is muscle wastage and the accompanied loss of strength, is one of the most weakening conditions of old age and it has no treatment.
The scientists propose that stimulating Mitofusin 2 activity would provide a good strategy through which to ameliorate sarcopenia.